The Right Rx Based on the Right Dx at the Right Time

The Oncomine™ Dx Target Test is the first FDA-approved targeted NGS that can detect multiple gene mutations for non-small cell lung cancer (NSCLC) to aid in the selection of specific targeted therapies for NSCLC patients. Learn More >>

Cancer Genetics Acquires vivoPharm to Help Expedite Drug Development & Improve the Lives of Patients Worldwide

Learn more about how CGI’s the newly combined companies are at the forefront of precision oncology development.

North American Precision Oncology Technology Innovation Award

CGIX was awarded and highlighted as the leader in technology innovation for precision oncology based on a combination of business model and technology factors.
Please read the full report >>

Comprehensive Testing. Integrated Results.

CGI’s Complete Program offers a unique suite of common and proprietary tests intended to assist clinicians in determining treatment to improve patient outcomes. Each program integrates the most recent diagnostic and prognostic biomarkers across multiple methodologies. Learn More >>

CGI is a Testing Provider for Ventana PD-L1 (SP142) Assay

CGI is a provider for PD-L1 (SP142) complimentary diagnostic approved for TECENTRIQ™ drug (Genentech) for treatment of Urothelial Carcinoma patients. Learn More >>

Focus::Lymphoma^TM NGS Panel for B-cell Lymphomas

CGI’s Focus::Lymphoma^TM Next Generation Sequencing panel is now available for routine clinical management and therapy selection for lymphoma patients, giving hope to patients who at times have failed first line treatments. Learn More >>

Focus::Oncomine^TM NGS Panel For Solid Tumors

CGI’s Focus::Oncomine^TM NGS panel is CLIA validated and available for both clinical care and for clinical trials being performed by biotech and pharmaceutical companies. Learn More >>

FDA-Approved PD-L1 Testing Now Available

The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for KEYTRUDA® (pembrolizumab) is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer. Learn More>>

CGI Now Offers FDA-cleared Tissue of Origin^® Test

The Tissue of Origin^® test, formally a Pathwork test, is a microarray-based gene expression test that aids in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers. It’s the only FDA-cleared test of its type, and is a Medicare-reimbursed test. Learn More >>

Latest News from CGI

Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a lea[...] Read More...
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a lea[...] Read More...
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a lea[...] Read More...
Cancer Genetics Issues Letter to Shareholders

RUTHERFORD, N.J., Jan. 16, 2019 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a lea[...] Read More...

The Right Rx Based on the Right Dx at the Right Time

Cancer Genetics Acquires vivoPharm to Help Expedite Drug Development & Improve the Lives of Patients Worldwide

North American Precision Oncology Technology Innovation Award

Comprehensive Testing. Integrated Results.

CGI is a Testing Provider for Ventana PD-L1 (SP142) Assay

Focus::Lymphoma^TM NGS Panel for B-cell Lymphomas

Focus::Oncomine^TM NGS Panel For Solid Tumors

FDA-Approved PD-L1 Testing Now Available

CGI Now Offers FDA-cleared Tissue of Origin^® Test

Latest News from CGI

Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock

Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock

Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock

Cancer Genetics Issues Letter to Shareholders

Our Research

An Introduction to FHACT^®: Our FISH- based HPV-Associated Cancer Test

Collaborations

My CGI Reports

Excellence in Oncology

Our Media

Meet the CGI Team

Order a Test

Latest News from CGI

Our Research

An Introduction to FHACT®: Our FISH- based HPV-Associated Cancer Test

Collaborations

My CGI Reports

Excellence in Oncology

Our Media

Meet the CGI Team

Order a Test

An Introduction to FHACT^®: Our FISH- based HPV-Associated Cancer Test